Lyka Labs receives product permission for Tofacitinib Ointment

Lyka Labs has announced a significant development as it receives product permission from the Central Drugs Standard Control Organization of India. The permission is for the manufacture and marketing of Tofacitinib Ointment 2% w/w.

This regulatory milestone comes after Lyka Labs successfully completed a clinical trial involving 125 patients across 8 Clinical Trial Centers within India. The product permission signifies a significant step for the company, expanding its portfolio and potentially offering valuable solutions in the pharmaceutical market.

Stay tuned for further updates from Lyka Labs as it progresses with the launch and marketing of Tofacitinib Ointment 2% w/w.